Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

by Conte, Pierfranco , Lu, Yen-Shen , Rugo, Hope S , Inoue, Kenichi , Pápai, Zsuzsanna , André, Fabrice , Loibl, Sibylle , Takahashi, Masato , Ciruelos, Eva , Iwata, Hiroji , Hirawat, Samit , Kaufman, Bella , Juric, Dejan , Longin, Anne-Sophie , Campone, Mario , Yamashita, Toshinari , Mayer, Ingrid A , Wilke, Celine , Rubovszky, Gabor , Mills, David

in Adult / Aged / Aged, 80 and over / Antineoplastic Agents, Hormonal - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Antitumor activity / Breast cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - genetics / Cancer therapies / Chemotherapy / Class I Phosphatidylinositol 3-Kinases - genetics / Cyclin-dependent kinases / Diabetes / Diarrhea / Diarrhea - chemically induced / Endocrine therapy / Epidermal growth factor / ErbB-2 protein / Female / Fulvestrant / Fulvestrant - adverse effects / Fulvestrant - therapeutic use / Hormones / Humans / Hyperglycemia / Kinases / Metastasis / Middle Aged / Mutation / Patients / Progression-Free Survival / Receptor, ErbB-2 / Receptors, Estrogen / Receptors, Progesterone / Survival / Thiazoles - adverse effects / Thiazoles - therapeutic use / Tumors

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019

Confirm

Do you wish to request the book?

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Conte, Pierfranco,

Lu, Yen-Shen,

Rugo, Hope S,

Inoue, Kenichi,

Pápai, Zsuzsanna,

André, Fabrice,

Loibl, Sibylle,

Takahashi, Masato,

Ciruelos, Eva,

Iwata, Hiroji,

Hirawat, Samit,

Kaufman, Bella,

Juric, Dejan,

Longin, Anne-Sophie,

Campone, Mario,

Yamashita, Toshinari,

Mayer, Ingrid A,

Wilke, Celine,

Rubovszky, Gabor,

Mills, David

2019

Overview

PIK3CA mutations occur in approximately 40% of patients with hormone receptor–positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant led to a median progression-free survival of 11 months, as compared with 5.7 months with placebo plus fulvestrant. Hyperglycemia, rash, and diarrhea were more common with alpelisib.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Agents, Hormonal - therapeutic use

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Antitumor activity